This site is optimised for modern browsers. For the best experience, please use Google Chrome, Mozilla Firefox, or Microsoft Edge.

Beta

This is a new site which is still under development. We welcome your feedback, which will help improve it.

Feedback form

Drug combination could be effective for treatment resistant gonorrhoea

 
Drug combination could be effective for treatment resistant gonorrhoea

NIHR-funded researchers comparing treatments for gonorrhoea have identified a drug combination that could be an effective back-up for patients not responding to current therapy.

The research team, from University Hospitals Birmingham, found that a treatment of the antibiotic gentamicin with azithromycin worked almost as well as the currently used ceftriaxone for genital gonorrhoea.       

The study, today published in The Lancet, is the first randomised controlled trial to compare the two treatments for the sexually transmitted infection amid fears of growing resistance to ceftriaxone.

Public Health England (PHE) recently reported that it was investigating two cases of gonorrhoea in two women with similar resistance patterns to the antibiotics ceftriaxone and azithromycin, which are used as the first line treatment.

Professor Jonathan Ross, chief investigator of the Birmingham trial, said: “Our current antibiotic treatment for gonorrhoea is beginning to fail and experience with previous drugs strongly suggests that this could become a widespread problem. Our trial has found that gentamicin combined with azithromycin works almost as well as ceftriaxone with azithromycin for genital gonorrhoea, but did not clear throat or rectal gonorrhoea as effectively.

“We believe ceftriaxone should remain the first line treatment for gonorrhoea, with gentamicin as an alternative particularly for patients with genital infection, and those who are allergic or intolerant to ceftriaxone. But further research is required to identify and test new alternatives to ceftriaxone for the treatment of gonorrhoea.” 

In the trial, performed in 14 sexual health clinics in England, 720 participants were randomised to receive either injections of gentamicin, or the current treatment of ceftriaxone intravenously, with both groups also given a single dose of azithromycin by mouth.

Overall 98% of participants given ceftriaxone had their gonorrhoea cured, compared to 91% given gentamicin, a difference of 7%. Therefore, it is likely that doctors will continue to use ceftriaxone (plus azithromycin) as their preferred treatment. Gentamicin did have a cure rate of 94% for genital gonorrhoea and so it might be useful when ceftriaxone is not available, or inappropriate to use.

The study also indicates that current widely used treatment of 1 gram azithromycin, used in combination with both drugs, is probably not enough to prevent resistance developing , and its use globally as part of dual combination therapy for gonorrhoea should be reviewed.  In January this year the British Association for Sexual Health and HIV changed the national gonorrhoea treatment guideline to omit the azithromycin (and use a larger dose of ceftriaxone instead) to reflect the trial results.

If treated early gonorrhoea is unlikely to lead to any complications or long-term problems. However, without treatment, it can spread to other parts of the body and cause serious health issues.

Professor Hywel Williams, Director of the NIHR’s Health Technology Assessment Programme, which funded the study, said: “It’s very worrying that cases of treatment resistant gonorrhoea are now appearing across the globe. This research provides important new evidence that suggests that gentamicin with azithromycin could become a second-line treatment for patients who are resistant to ceftriaxone with this infectious disease.

“The NIHR is committed to research in areas of greatest health need, such as AMR. This research is one of a number of studies we've funded over the last few years in this vital area, in our sustained effort to tackle this worldwide threat.”

The researchers say further research into developing a preventative or therapeutic vaccine is crucial due to increasing resistance and limited future antibiotic options. 

More information on the study is available on the NIHR Journals Library.